Revolution Medicines Inc. (RVMD)
Revolution Medicines Got Its Breakthrough—What Moves It Next?
Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan
Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer. RVMD's multi-selective approach addresses a broad spectrum of RAS mutations, positioning RASONQUE as a potential blockbuster with significant market opportunity. Despite a strong cash position ($3.9B), RVMD will incur substantial losses through 2028, with profitability only projected in 2029 as revenue ramps from global expansion.
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer
Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma.
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis
The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.
High Risk, High Reward: Inside The Revolution Medicines Bull Case
Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player, anchored by its RAS(ON) inhibitor platform. RVMD's robust $3.9 billion cash position and additional committed capital support aggressive pipeline expansion and commercial launch readiness, reducing near-term dilution risk. Daraxonrasib's potential FDA approval and commercial launch in pancreatic cancer could fundamentally transform RVMD's financial profile and validate its broader RAS-targeted strategy.
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.
Revolution Medicines Q2 Earnings Call Highlights
Revolution Medicines NASDAQ: RVMD said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer.
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
